Literature DB >> 16330146

Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity.

Ouissame Mnie-Filali1, Mostafa El Mansari, Agnès Espana, Connie Sànchez, Nasser Haddjeri.   

Abstract

The present in vivo electrophysiological studies in anesthetized rat were undertaken to assess the effects of the selective serotonin (5-HT) reuptake inhibitor (SSRI) escitalopram alone or in combination with the R-citalopram (the S- and R-enantiomers of citalopram), on both long-term potentiation (LTP) in the CA(1) region of dorsal hippocampus and spontaneous firing activity of dorsal raphe (DR) 5-HT neurons. At the postsynaptic level, neither escitalopram (10 mg/kg, i.p.) nor R-citalopram (20 mg/kg, i.p.) modified basal synaptic transmission but only escitalopram impaired LTP expression. Importantly, R-citalopram counteracted significantly the escitalopram-induced decrease of LTP. At the pre-synaptic level, escitalopram (25-75 microg/kg, i.v.) dose-dependently suppressed the spontaneous firing activity of DR 5-HT neurons and this suppressant effect was significantly prevented by a prior injection of R-citalopram (10 mg/kg, i.p.). These results support a role of allosteric binding sites of 5-HT transporter in the regulation of long-lasting CA(1) synaptic plasticity and DR 5-HT neuronal firing activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330146     DOI: 10.1016/j.neulet.2005.10.044

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

2.  Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.

Authors:  Jennifer D Cooke; Hannah M Cavender; Hope K Lima; Lawrence M Grover
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

Review 3.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Authors:  Dorothy K Sit; James M Perel; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

Review 5.  The pharmacology of neuroplasticity induced by non-invasive brain stimulation: building models for the clinical use of CNS active drugs.

Authors:  Michael A Nitsche; Florian Müller-Dahlhaus; Walter Paulus; Ulf Ziemann
Journal:  J Physiol       Date:  2012-08-06       Impact factor: 5.182

6.  Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study.

Authors:  Alan G Wade; Gordon M Crawford; Ann Yellowlees
Journal:  BMC Psychiatry       Date:  2011-03-16       Impact factor: 3.630

7.  Comparative efficacy of escitalopram in the treatment of major depressive disorder.

Authors:  Mazen K Ali; Raymond W Lam
Journal:  Neuropsychiatr Dis Treat       Date:  2011-02-01       Impact factor: 2.570

8.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

9.  Astroglial Control of the Antidepressant-Like Effects of Prefrontal Cortex Deep Brain Stimulation.

Authors:  A Etiévant; C Oosterhof; C Bétry; E Abrial; M Novo-Perez; R Rovera; H Scarna; C Devader; J Mazella; G Wegener; C Sánchez; O Dkhissi-Benyahya; C Gronfier; V Coizet; J M Beaulieu; P Blier; G Lucas; N Haddjeri
Journal:  EBioMedicine       Date:  2015-07-07       Impact factor: 8.143

Review 10.  Cellular and molecular mechanisms in the long-term action of antidepressants.

Authors:  Giorgio Racagni; Maurizio Popoli
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.